Phase I and II SBIR Grants Issued to Biosearch
News Jun 18, 2007
Biosearch Technologies, Inc. (BTI) has announced that two staff scientists have been awarded Small Business Innovation Research (SBIR) Grants by the National Institutes of Health (NIH) in Bethesda, Maryland.
The first, a $750,000 SBIR Phase II grant funded by the National Institute of General Medical Sciences (NIGMS), will fund the development of fluorescence-based reporter assays incorporating a recently discovered azoreductase that has been shown to release high-quality fluorescent signals. This work has important implications for significantly increasing the data generated by existing high-throughput drug screening technologies through the multiplexing of two or more reporter assays in one screening run.
The second, a $100,000 SBIR Phase I grant again funded by the National Institute of General Medical Sciences (NIGMS), will fund the development of technology for engineering bacterial chromosomes utilizing synthetic DNA. Outgrowths of this technology will enable the facile engineering of bacterial strains for a variety of applications including bioremediation, natural products and biofuel production.
Research Team Discovers Compound that Stops Cancer From SpreadingNews
Using a mouse model, OHSU physician-scientists lead effort to hone a drug that inhibits cancer cells from spreading to other areas in the body.READ MORE
Mechanism Controlling Multiple Sclerosis Risk IdentifiedNews
Researchers at Karolinska Institutet have now discovered a new mechanism of a major risk gene for multiple sclerosis (MS) that triggers disease through so-called epigenetic regulation. They also found a protective genetic variant that reduces the risk for MS through the same mechanism.
Synthetic DNA Shuffling Enzyme Outpaces Natural CounterpartNews
A new synthetic enzyme, crafted from DNA rather than protein, flips lipid molecules within the cell membrane, triggering a signal pathway that could be harnessed to induce cell death in cancer cells. Researchers say their lipid-scrambling DNA enzyme is the first in its class to outperform naturally occurring enzymes – and does so by three orders of magnitudeREAD MORE